ATE243186T1 - Verbindungen , die auf anorganische ionen- rezeptoren wirken - Google Patents

Verbindungen , die auf anorganische ionen- rezeptoren wirken

Info

Publication number
ATE243186T1
ATE243186T1 AT97922601T AT97922601T ATE243186T1 AT E243186 T1 ATE243186 T1 AT E243186T1 AT 97922601 T AT97922601 T AT 97922601T AT 97922601 T AT97922601 T AT 97922601T AT E243186 T1 ATE243186 T1 AT E243186T1
Authority
AT
Austria
Prior art keywords
inorganic ion
compounds acting
compounds
ion receptors
receptor
Prior art date
Application number
AT97922601T
Other languages
English (en)
Inventor
Scott T Moe
Wagenen Bradford C Van
Eric G Delmar
Richard Trovato
Manuel F Balandrin
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Application granted granted Critical
Publication of ATE243186T1 publication Critical patent/ATE243186T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Prostheses (AREA)
  • Steroid Compounds (AREA)
AT97922601T 1996-05-01 1997-04-30 Verbindungen , die auf anorganische ionen- rezeptoren wirken ATE243186T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1667396P 1996-05-01 1996-05-01
PCT/US1997/007371 WO1997041090A1 (en) 1996-05-01 1997-04-30 Inorganic ion receptor-active compounds

Publications (1)

Publication Number Publication Date
ATE243186T1 true ATE243186T1 (de) 2003-07-15

Family

ID=21778338

Family Applications (3)

Application Number Title Priority Date Filing Date
AT02018228T ATE352537T1 (de) 1996-05-01 1997-04-30 Verbindungen, die auf anorganische ionen- rezeptoren wirken
AT07000764T ATE430123T1 (de) 1996-05-01 1997-04-30 Inorganische am ionen-rezeptor aktive verbindungen
AT97922601T ATE243186T1 (de) 1996-05-01 1997-04-30 Verbindungen , die auf anorganische ionen- rezeptoren wirken

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT02018228T ATE352537T1 (de) 1996-05-01 1997-04-30 Verbindungen, die auf anorganische ionen- rezeptoren wirken
AT07000764T ATE430123T1 (de) 1996-05-01 1997-04-30 Inorganische am ionen-rezeptor aktive verbindungen

Country Status (12)

Country Link
US (3) US5981599A (de)
EP (1) EP0907631B1 (de)
JP (2) JP4117506B2 (de)
AT (3) ATE352537T1 (de)
AU (1) AU731146C (de)
DE (3) DE69737303T2 (de)
DK (1) DK0907631T3 (de)
ES (3) ES2201300T3 (de)
HK (2) HK1051995A1 (de)
PT (1) PT907631E (de)
TW (1) TW561150B (de)
WO (1) WO1997041090A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DK0907631T3 (da) * 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser
KR100860655B1 (ko) * 1996-07-08 2008-09-26 기린 파마 가부시끼가이샤 칼슘 수용체 활성 화합물
IL133942A0 (en) * 1997-07-09 2001-04-30 Akzo Nobel Nv Chelating agents and their manganic chelates
AU1558899A (en) * 1997-11-10 1999-05-31 F. Hoffmann-La Roche Ag Isoquinoline derivatives for use against cns disorders
FR2800735B1 (fr) * 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
US7176243B2 (en) 2000-06-02 2007-02-13 The General Hospital Corporation CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
FR2812875B1 (fr) * 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6979559B2 (en) * 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
US6463883B1 (en) 2000-10-12 2002-10-15 Marical, Llc Methods for raising pre-adult anadromous fish
US6475792B1 (en) 2000-10-12 2002-11-05 Marical, Llc Methods for raising pre-adult anadromous fish
US6979558B2 (en) * 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in Atlantic salmon
US6951739B2 (en) * 2000-10-12 2005-10-04 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
EP1324651B1 (de) * 2000-10-12 2008-02-13 Marical, Inc. Verfahren zur züchtung von nichterwachsenen anadromen fischen
US6481379B1 (en) * 2000-10-12 2002-11-19 Marical, Llc Methods for raising pre-adult anadromous fish
US6463882B1 (en) * 2000-10-12 2002-10-15 Marical, Llc Growing marine fish in freshwater
US7101988B2 (en) * 2000-10-12 2006-09-05 Marical, Inc. Polyvalent cation-sensing receptor in Atlantic salmon
EP1434482B9 (de) * 2001-10-11 2007-11-28 Marical, Inc. Verfahren zum züchten und imprimieren von fischen mittels eines geruchstoffes
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
TR201910177T4 (tr) 2003-09-12 2019-08-21 Amgen Inc Bir sinakalset HCl içeren hızlı çözünme formülasyonu.
EG23529A (en) * 2003-11-05 2006-04-11 Amri Moosa E Al System and method to broadcast the video or tv anddisplaying on pc tv by choosing the required prog ram from the internet
WO2005065050A2 (ja) 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation ２環化合物
WO2005115975A1 (ja) 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. アリールアルキルアミン化合物及びその製法
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
CN101184508A (zh) * 2005-03-17 2008-05-21 安姆根有限公司 减少钙化的方法
DK1882684T3 (en) * 2005-05-19 2015-01-05 Astellas Pharma Inc PYRROLIDE INGREDIENTS OR SALTS THEREOF
CN101180261A (zh) * 2005-05-23 2008-05-14 特瓦制药工业有限公司 用于制备盐酸西那卡塞晶型ⅰ的方法
JP5309014B2 (ja) 2006-03-23 2013-10-09 アムジエン・インコーポレーテツド シナカルセットの多形体の製造および使用のための方法および組成物
CN101437490A (zh) 2006-04-20 2009-05-20 安美基公司 稳定乳液配方
ES2449340T3 (es) 2007-03-30 2014-03-19 Amgen Inc. Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales
ES2499015T3 (es) * 2007-05-08 2014-09-26 Ajinomoto Co., Inc. Agente profiláctico o terapéutico para la diarrea
CA2701792A1 (en) * 2007-10-15 2009-04-23 Amgen Inc. Calcium receptor modulating agents
WO2010010359A2 (en) * 2008-07-24 2010-01-28 Cilpa Limited A process for the preparation of cinacalcet and its salts
WO2010042642A1 (en) * 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
US8785494B2 (en) 2009-05-27 2014-07-22 Leo-Pharma A/S Calcium sensing receptor modulating compounds and pharmaceutical use thereof
CA2762137A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010136036A2 (en) * 2009-05-27 2010-12-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
RU2599788C2 (ru) 2010-06-30 2016-10-20 Лео Фарма А/С Новая полиморфная форма кальцимиметического соединения
JP5968880B2 (ja) 2010-06-30 2016-08-10 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
EP2643291A2 (de) 2010-11-26 2013-10-02 Leo Pharma A/S Casr-aktive verbindungen
RU2013128968A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительного рецептора
US9382216B2 (en) 2011-03-10 2016-07-05 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
WO2013136288A1 (en) * 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2276618A (en) * 1942-03-17 N-phenylaliphatic bihxdroxithenyl-
CH217009A (fr) * 1940-10-25 1941-09-30 Anonyme Taubert Freres Societe Boîte de montre.
US2930731A (en) * 1952-04-08 1960-03-29 Upjohn Co Bis[beta-(ortho-hydrocarbonoxyphenyl)iso-propyl]amines
BE570596A (de) * 1957-08-26
NL281782A (de) * 1961-08-14
US3262977A (en) * 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
NL293886A (de) * 1962-06-19 1965-04-12 Merck Ag E
US3318952A (en) * 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3459767A (en) * 1965-08-10 1969-08-05 Pfizer & Co C Aminomethylindoles
GB1109924A (en) * 1965-11-29 1968-04-18 Roche Products Ltd Novel substituted diphenylalkyl amines and a process for the manufacture thereof
DE1618005A1 (de) * 1966-09-22 1971-09-09 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen
CH480791A (de) * 1967-01-17 1969-11-15 Ciba Geigy Schädlingsbekämpfungsmittel
GB1263987A (en) * 1969-05-30 1972-02-16 Allen & Hanburys Ltd Phenethylamine derivatives
GB1448437A (en) * 1973-02-24 1976-09-08 Beecham Group Ltd Diphenylpropylamines
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US4000197A (en) * 1973-07-23 1976-12-28 The University Of Iowa Research Foundation Asymmetric synthesis of phenylisopropylamines
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (de) * 1974-03-08 1982-06-04
US4014937A (en) * 1974-08-26 1977-03-29 Pfizer Inc. 3,4-And 3,5-dialkoxyphenethylamines
HU169507B (de) * 1974-09-25 1976-12-28
US3987201A (en) * 1974-12-24 1976-10-19 Eli Lilly And Company Method for treating arrhythmia
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
JPS5390272A (en) * 1977-01-13 1978-08-08 Sendai Fukusokan Kagaku Kenkiy Method of producing optically active salsolizine
US4608391A (en) * 1977-07-05 1986-08-26 Cornell Research Foundation Inc. Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof
US4289787A (en) * 1977-12-19 1981-09-15 Eli Lilly And Company Quaternary ammonium antiarrhythmic drugs
DD144050A5 (de) * 1978-06-05 1980-09-24 Ciba Geigy Ag Verfahren zur herstellung von n-alkylierten aminoalkoholen
DE2825961A1 (de) * 1978-06-14 1980-01-03 Basf Ag Fungizide amine
IL57672A (en) * 1978-07-03 1983-03-31 Lilly Co Eli Phenethanolamines,their preparation and pharmaceutical compositions containing the same
US4391826A (en) * 1978-07-03 1983-07-05 Eli Lilly And Company Phenethanolamines, compositions containing the same, and method for effecting weight control
ZA794872B (en) * 1978-09-20 1980-11-26 Schering Corp A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it
FR2436773A1 (fr) * 1978-09-22 1980-04-18 Roussel Uclaf Nouveaux derives du 3-(aminoethyl) phenol et leurs sels, procede de preparation et application a titre de medicaments
US4360511A (en) * 1978-11-29 1982-11-23 Medi-Physics, Inc. Amines useful as brain imaging agents
DD150456A5 (de) * 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
US4338333A (en) * 1979-06-16 1982-07-06 Beecham Group Limited Ethanamine derivatives their preparation and use in pharmaceutical compositions
JPS603387B2 (ja) * 1980-07-10 1985-01-28 住友化学工業株式会社 新規光学活性イミダゾリジン−２−オン誘導体およびその製法
HU183430B (en) * 1981-05-12 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
US4591605A (en) * 1981-11-10 1986-05-27 Research Foundation Of State University Of New York Method and ingestible formulation for inhibiting the secretion of stomach acid
US4658060A (en) * 1982-04-26 1987-04-14 Schering Corporation Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide
DE3225879A1 (de) * 1982-07-10 1984-01-12 Basf Ag, 6700 Ludwigshafen Trans-3-(4'-tert.-butylcyclohexyl-1')-2-methyl-1-dialkyl-aminopropane, ihre herstellung und verwendung als arzneimittel
CA1258454A (en) * 1982-08-10 1989-08-15 Leo Alig Phenethanolamines
US4647446A (en) * 1982-08-18 1987-03-03 The Regents Of The University Of California Rapid brain scanning radiopharmaceutical
JPS5950358A (ja) * 1982-09-14 1984-03-23 Sumitomo Chem Co Ltd 光学活性なカルボン酸をグラフトしたクロマトグラフ充填剤およびそれを用いる鏡像体混合物の分離法
US4677101A (en) * 1983-09-26 1987-06-30 Merck & Co., Inc. Substituted dihydroazepines useful as calcium channel blockers
US4661635A (en) * 1983-11-21 1987-04-28 Mcneilab, Inc. Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives
US5334628A (en) * 1984-06-09 1994-08-02 Kaken Pharmaceutical Co., Ltd. Amine derivatives, processes for preparing the same and fungicides containing the same
US4587253A (en) * 1984-07-30 1986-05-06 Merck & Co., Inc. Bridged pyridine compounds useful as calcium channel blockers and analgesics
US4609494A (en) * 1985-02-21 1986-09-02 Merck & Co., Inc. 5-acetyl-3,4,5,6-tetrahydro-4-oxo-2,6-methano-2H-1,3,5-benzothiazocine(benzodiazocine)-11-carboxylates useful as calcium channel blockers
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8522186D0 (en) * 1985-09-06 1985-10-09 Erba Farmitalia Cycloalkyl-substituted 4-aminophenyl derivatives
DE3541181A1 (de) * 1985-11-21 1987-05-27 Basf Ag Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US4675321A (en) * 1986-02-07 1987-06-23 Merck & Co., Inc. Substituted pyrimidines useful as calcium channel blockers
US5034514A (en) * 1986-03-17 1991-07-23 Cetus Corporation Novel cross-linking agents
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4808718A (en) * 1986-05-06 1989-02-28 Merck & Co., Inc. Fused polycyclic and bridged compounds useful as calcium channel blockers
HU200591B (en) * 1986-07-11 1990-07-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds
US4797411A (en) * 1986-07-18 1989-01-10 Farmitalia Carlo Erba S.P.A. Cycloalkyl-substituted 4-pyridyl derivatives and use as aromatase inhibitors
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5064657A (en) * 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
EP0270376B1 (de) * 1986-12-04 1992-09-30 Asahi Kasei Kogyo Kabushiki Kaisha Vom Calcitonin-Gen abgeleitete Peptidderivate
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
US4916145A (en) * 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
DE68924372T2 (de) * 1988-01-11 1996-05-09 Amylin Pharmaceuticals Inc Behandlung von diabetes mellitus typ 2.
US5001251A (en) * 1988-01-15 1991-03-19 E. R. Squibb & Sons, Inc. Optical resolution of DL-3-acylthio-2-methylpropanoic acid
WO1989009834A1 (en) * 1988-04-04 1989-10-19 The Salk Institute Biotechnology/Industrial Associ Calcium channel compositions and methods
US5082837A (en) * 1988-06-28 1992-01-21 Merrell Dow Pharmaceuticals Lactamimides as calcium antagonists
US4925873A (en) * 1988-09-01 1990-05-15 E. R. Squibb & Sons, Inc. Method of treating skin injuries using thromboxane A2 receptor antagonists
JPH02200658A (ja) * 1989-01-28 1990-08-08 Kumiai Chem Ind Co Ltd Ｎ―（置換）ベンジルカルボン酸アミド誘導体及び除草剤
US5011834A (en) * 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
EP0597830A1 (de) * 1989-07-03 1994-05-25 New York University Nyu Medical Center Verwendung von Polyaminen als die Ionenkanäle regulierenden Wirkstoffe
GB8915712D0 (en) * 1989-07-08 1989-08-31 Macintyre Iain Medical treatment
US5021599A (en) * 1989-08-31 1991-06-04 Serpentix Conveyor Corporation Redox-responsive anion receptors
US5053337A (en) * 1989-10-30 1991-10-01 Neurogenetic Corporation DNA encoding an α2B -adrenergic receptor
EP0507863A4 (en) * 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
JP2818958B2 (ja) * 1990-02-23 1998-10-30 塩野義製薬株式会社 ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
WO1992007829A1 (en) * 1990-11-02 1992-05-14 The Upjohn Company Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
CA2099245A1 (en) * 1991-02-08 1992-08-09 Stanley M. Goldin Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
DE69206306T2 (de) * 1991-04-08 1996-06-13 Sumitomo Chemical Co Optisch aktive Sekundär-Aminverbindung, Verfahren zur Herstellung einer optisch aktiven Sekundär-Aminverbindung und Verfahren zur Herstellung optisch aktiver Carbonsäure durch die Verwendung dieser Verbindung.
CN1065857A (zh) * 1991-04-16 1992-11-04 北京农业大学 光活性1,1′-联萘-2,2′-二酚的合成方法
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
JP4555401B2 (ja) * 1991-08-23 2010-09-29 エヌピーエス ファーマシューティカルズ インコーポレイテッド カルシウム受容体に活性なアリールアルキルアミン
DK1281702T3 (da) * 1991-08-23 2006-04-18 Nps Pharma Inc Calciumreceptoraktive molekyler
CA2123403C (en) * 1991-11-12 2002-02-05 Brian T. O'neill Acyclic ethylenediamine derivatives as substance p receptor antagonists
US5407961A (en) * 1991-12-30 1995-04-18 Janssen Pharmaceutica N.V. α-substituted benzenemethanamine derivatives and pharmaceutical use
AU3588693A (en) * 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors
WO1994018959A1 (en) * 1993-02-23 1994-09-01 Brigham And Women's Hospital, Inc. Calcium receptor-active molecules
GB9326403D0 (en) * 1993-12-24 1994-02-23 Oxford Asymmetry Ltd Improvements in or relating to chiral syntheses
US5504253A (en) * 1994-07-15 1996-04-02 Nps Pharmaceuticals, Inc. Amine preparation
PT1203761E (pt) * 1994-10-21 2005-04-29 Nps Pharma Inc Compostos activos do receptor de calcio
US5648541A (en) * 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
DK0907631T3 (da) * 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser

Also Published As

Publication number Publication date
US6710088B2 (en) 2004-03-23
ES2280460T3 (es) 2007-09-16
DE69722934D1 (de) 2003-07-24
EP0907631A1 (de) 1999-04-14
TW561150B (en) 2003-11-11
AU731146B2 (en) 2001-03-22
US20030008876A1 (en) 2003-01-09
ES2201300T3 (es) 2004-03-16
ATE430123T1 (de) 2009-05-15
EP0907631B1 (de) 2003-06-18
JP2008115184A (ja) 2008-05-22
DE69722934T2 (de) 2004-05-27
DK0907631T3 (da) 2003-09-22
JP2000509395A (ja) 2000-07-25
JP4117506B2 (ja) 2008-07-16
US6342532B1 (en) 2002-01-29
DE69739388D1 (de) 2009-06-10
JP4431609B2 (ja) 2010-03-17
DE69737303T2 (de) 2007-08-30
PT907631E (pt) 2003-10-31
DE69737303D1 (de) 2007-03-15
AU2822997A (en) 1997-11-19
ATE352537T1 (de) 2007-02-15
HK1102806A1 (en) 2007-12-07
US5981599A (en) 1999-11-09
AU731146C (en) 2005-02-03
HK1051995A1 (en) 2003-08-29
WO1997041090A1 (en) 1997-11-06
ES2326004T3 (es) 2009-09-28

Similar Documents

Publication Publication Date Title
ATE243186T1 (de) Verbindungen , die auf anorganische ionen- rezeptoren wirken
WO1996012697A3 (en) Calcium receptor-active compounds
HK1012620A1 (en) Calcium receptor-active arylalkyl amines.
AU6602296A (en) Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
YU59098A (sh) Derivati spiro-piperidina, postupak njihovog dobijanja, njihova upotreba u proizvodnji leka korisnog za lečenje ili prevenciju bolova, upalnih procesa, migrene, povraćanja i postherpetične neuralgije i farmaceutski sastav koji ih sadrži
FR2773075B1 (fr) Utilisation d'activateurs de ppar-gamma en dermatologie
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
DK1482973T3 (da) Fremgangsmåde til modulering af CD200-receptorer
WO2003014321A3 (en) Compositions and methods for modulation of darpp-32 phosphorylation
DK0778890T3 (da) DNA, som koder for en human calciumkanal-alpha-1E-underenhed
NO994850L (no) Farmakologiske midler
YU41998A (sh) Tetrahidrobetakarbolinska jedinjenja
DE59910781D1 (de) Verteiles steuerungssystem mit lagebestimmung der komponenten
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
PT628033E (pt) Derivados de benzodiazepina uteis como antagonistas dos receptores-cck
DE60033576D1 (de) Methoden zum screening knochenmorphogenetishemimetika
DK1506313T3 (da) Fremgangsmåder til screening af modulatorer af den mitokondrielle NAD-afhængige deacetylase SIRT3
EP1258471A3 (de) Verbindungen, die auf anorganische Ionen-Rezeptoren wirken
CA2253407A1 (en) Inorganic ion receptor-active compounds
AU2003221878A8 (en) G-protein coupled receptor ligands and methods
DE69714247D1 (de) Heterozyklische verbindungen
ATE342055T1 (de) Verwendung von steroidalen estrogenrezeptorantagonisten zur männlichen fertilitätskontrolle
ES2169161T3 (es) Metodologia de evaluacion de deposito de la delta-endotoxina del bacillus thuringiensis.
TR199900672T2 (xx) Benzotiofenlerin sentezi i�in i�lem.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0907631

Country of ref document: EP